count 128 × 10 9 /l, calcium 15 mg/d, LDH 1654 IU/l, ALP 708 IU/l, alanine aminotransferase 708 U/l and asparto-aminotransferase 172 U/l. Chest radiographs disclosed left pleural effusion and lytic bone lesions on the 3rd and 9th ribs. A CT scan showed hepatosplenomegaly with multiple rounded intraparenchymal lesions and retroperitoneal lymphadenopathy. Two pleural effusion samples and a bone marrow aspirate failed to demonstrate neoplastic cells by cytological or immunophenotypic means. A liver biopsy performed under ultrasound guidance showed chronic active hepatitis and focal infiltration by a large cell lymphoma. A diagnosis of high-grade NHL with bone metastasis and hypercalcemia, stage IVb, IPI 4 and Karnofsky 30 was established. Intravenous calcitonin and steroid therapy was started, followed some days later by chemotherapy (PROMACE/cytaBON protocol).
The patient died 24 h after the chemotherapy was initiated, on the 13th hospital day. The autopsy showed large confluent nodules in spleen and liver, as well as local retroperitoneal lymph nodes, bilateral adrenal and bone marrow neoplastic involvement. Strikingly, there were no additional sites. Flow cytometry of a cellular suspension obtained from one of the hepatic nodules showed CD19 + CD20 + CD22 + sKappa + HLA-DR + CD45RA + cells, with no expression of CD5, CD34, CD10, CD103, CD56, CD122 or CD3. The tumor was classified as a diffuse large B cell lymphoma (REAL classification).
Clinicians should consider that the spectrum of HCV-related B cell clonal expansions may include high-grade lymphomas, with fulminant presentations in young patients like the one reported here; an uncommon event in the series reported so far. Further clinical, pathological and epidemiological studies are needed to assess the impact of B cell malignancies complicating the course of HCV infection and to set the guidelines for the appropriate surveillance in HVC-infected patients. It is Late relapse in BCR/ABL-positive patients after non-intensive chemotherapy TO 
THE EDITOR
The recent study by Brisco et al 1 shows that cases of Philadelphia (Ph) chromosome positive and negative adult acute lymphoblastic leukemia (ALL) can initially have similar drug resistance, determined by the degree of minimum residual disease (MRD) at the end of induction. In turn, another recent study Preudhomme et al 2 showed the importance of followup by RT-PCR of the BCR/ABL hybrid gene derived from t(9;22) that gives rise to the Ph chromosome, in predicting the outcome of these patients. However, other authors have described patients not submitted to allogeneic bone marrow transplantation as having a persistently positive BCR/ABL in prolonged complete hematologic remission (CR). 3 We present two cases of tardy relapsed BCR/ABL-positive ALL after conventional chemotherapy treatment indicating that when CR is achieved in these patients they can relapse much later on. certainly intriguing that the recent report of three patients in which intrasplenic B cell lymphomatous nodules were coincidentally discovered in the course of HCV infection, and whose survival after early splenectomy has been longer than 35 months. This finding must be taken into account in the assessment of MRD studies.
Case 1
A 37-year-old woman was diagnosed on 16 February 1990 with precursor B cell ALL (CD10
9 /l. The cytogenetic analysis was inconclusive because of insufficient samples. The patient was treated according to the German multicentric trial chemotherapeutic protocol adult ALL 03/87 of high risk 4 (due to age). Complete hematologic remission was achieved after induction and the treatment finished on 28 December 1992. From this moment she remained in CR until 9 February 1997 (96 months after the diagnosis, 95 months after achieving CR and 45.5 months after completing treatment) when she was diagnosed with relapsed B cell precursor ALL (CD10 + , CD20 + , HLADR + ), WBC 9.18 × 10 9 /l. Once again the cytogenetic study was inconclusive but mRNA of BCR/ABL P190 type (e1a2 junction) was detected by nested reverse-transcriptase polymerase chain reaction in mononuclear cells of the bone marrow (BM). All the molecular techniques performed in both cases were carried out according to procedures described previously, 5, 6 each study was repeated at least twice and negative controls were done in all cases. After this the patient was treated with chemotherapy according to the LAL-AR93 protocol of the Spanish group PETHEMA. 7 After induction, CR was achieved but the patient was still BCR/ABL-positive and the Ph chromosome was detected in one of 50 metaphases (both techniques in BM). After consolidation, a result of BCR/ABL + in BM with hematologic CR was still recorded. Autologous peripheral blood stem cell transplantation was carried out (the prouct of leukapheresis was also BCR/ABL + by nested RT-PCR) but the patient finally relapsed a second time on the 5 November 1997 and died 19 days later. 
Discussion
The cases described could corroborate the hypothesis that initially some BCR/ABL-positive patients are no more resistant to chemotherapy than negative patients but they can maintain a more or less quiescent number of cells which can later lead to relapse, after which the first of our two cases proved to be chemosensitive. Also, the importance of the BCR/ABL gene analysis becomes evident since, as occurred in both these cases, the cytogenetic study can be negative or uninformative and because of the poor prognosis of these patients they should receive more intensive therapy. It is also important to monitor these rearrangements over the entire treatment period since, as shown by these two patients, relapses can occur much later on which can be detected beforehand by molecular analysis as described by Brisco et al. 1 In turn, very recently BCR/ABL positive patients have been described who are permanently in CR after a mean follow-up of 36 months after achieving CR without receiving an allogeneic BM transplantation. These patients should be closely monitored since, as occurred in our two patients, they could suffer a very late relapse. We therefore consider it necessary to prolong the follow-up period of BCR/ABL + patients before one can correctly assess the significance of MRD in these patients.
